Cargando…

92418 Molecular imaging of the tumor microenvironment to predict response to combination treatment with immunotherapy in triple negative breast cancer

ABSTRACT IMPACT: Insights from this project will provide clinical guidance in treatment of immunotherapy in triple negative breast cancer and identify early imaging biomarkers of treatment response. OBJECTIVES/GOALS: Significant research that addresses monitoring and predicting patient response of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Napier, Tiara S., Hunter, Chanelle L., Song, Patrick N., Larimer, Benjamin M., Sorace, Anna G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Basic Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827709/ http://dx.doi.org/10.1017/cts.2021.455

Ejemplares similares

Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer
por: Napier, Tiara S., et al.
Publicado: (2022)

Molecular Imaging of Oxygenation Changes during Immunotherapy in Combination with Paclitaxel in Triple Negative Breast Cancer
por: Napier, Tiara S., et al.
Publicado: (2023)

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
por: Loizides, Sotiris, et al.
Publicado: (2023)

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer
por: Cao, Xu, et al.
Publicado: (2021)

Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
por: Kudelova, Eva, et al.
Publicado: (2022)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients
por: Alwan, Nada A. S., et al.
Publicado: (2019)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

56371 The Signaling Axis of Tumor Suppressor LKB1 in Triple Negative Breast Cancer
por: Nguyen, Khoa, et al.
Publicado: (2021)

Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells
por: Español, Alejandro, et al.
Publicado: (2022)

Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer
por: Huang, Pengfei, et al.
Publicado: (2023)

Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021)

Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
por: Li, Liying, et al.
Publicado: (2023)

Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer
por: Alečković, Maša, et al.
Publicado: (2023)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer
por: Zhang, Juan, et al.
Publicado: (2023)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Dimensional Analysis of CD44(High) CD24(Low) and Ki67 in Triple Negative Breast Cancer
por: Tan, Betty, et al.
Publicado: (2019)

The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer
por: Fan, Yiqi, et al.
Publicado: (2022)

Crosstalk between triple negative breast cancer and microenvironment
por: Smrekar, Karly, et al.
Publicado: (2023)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wesolowski, Jakub, et al.
Publicado: (2022)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer
por: Bai, Fang, et al.
Publicado: (2020)

4543 Glucocorticoid Receptors are essential effectors of TGFβ signaling in Triple Negative Breast Cancer
por: Kerkvliet, Carlos Jesus Perez, et al.
Publicado: (2020)

47982 Reversing the resistance to chemotherapy in White and Black patients with triple negative breast cancer (TNBC).
por: Gandhi, Shipra, et al.
Publicado: (2021)

Addendum: Crosstalk between triple negative breast cancer and microenvironment
por: Smrekar, Karly, et al.
Publicado: (2023)

Acute Exercise Increases NK Cell Mitochondrial Respiration and Cytotoxicity against Triple-Negative Breast Cancer Cells under Hypoxic Conditions
por: CHO, EUNHAN, et al.
Publicado: (2023)

Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model
por: Garg, Himani, et al.
Publicado: (2018)

Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies
por: Nahar, Saifun, et al.
Publicado: (2023)

Outcomes of Women with Non-Metastatic Triple-Negative Breast Cancer in Oman: A single-centre experience
por: Kumar, Shiyam, et al.
Publicado: (2019)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fja5bjtp3ve5htbk1s5fbqu8v5